

## **MS Prescription Referral Form**

Send your Rx to:			J	avella.c If you have qu concerns, please		
Date Medication Nee	ded: Ship To:		criber's Office Pick-up (store location):		<b>-7</b> n training armacy?	
1: Patient						
Patient Name: Birthdate:				-	_	
Soc. Sec. #: Preferred Phone:			G			
Alternate Caregiver Name:			Preferred Phone:	Zip		
The children caregives			ACK copy of ALL Insurance cards (Prescription and Me	dical)		
2: Prescrib		C Tax T NOTYT and Br	Act copy of ALL madrance cards (Frescription and Me	aicaij		
-						
Provider Name:						
Address:						
`						
3: Diagnos	is/Clinical Information   P	Please FAX recent cli	nical notes, Labs, Tests, with the prescription to expedi	te the Prior Auti	horizatior	
Diagnosis: CM G35 Multiple Sclerosis Other:			Number of relapses in past year:			
Has the patient been previously treated for this condition? Yes No			Last MRI date: Any MRI changes? Yes No			
Prior failed medicat	ion (medication and duration of treatment/	reason for d/c):	Inection training completed by: Novantrone:			
Patient currently on therapy? Yes No Medication(s):			Is patient's LVEF <50%? Yes No			
•	ing above medication before starting		What is lifetime (cumulative) Novantrone dose (mg/m2)?			
Yes No Discontinuation Date:			Copy of last CBC with differential:			
Is prescriber a Neuro	ologist? If no, please include neurology	y consult if available.	Is patient pregnant, nursing or planning pregnancy? Yes	es No N/A		
Diagnosis:	Other:		Serum Creatine Creatinine Clearance			
4: Prescrip	tion Information					
Medication	Dose/Strength		Sig	Qty.	Refills	
Avonex®	AVOSTARTGRIP Titration Kit 30mcg Prefilled Syringe #4 30mcg Pen #4	• Week 1: Inject 7 • Week 2: Inject 1 • Week 3: Inject 2 • Week 4: Inject	4 week supply	0		
Betaseron®	0.3mg vial	Inject 30mcg IM once weekly  Dose Titration:  • Weeks 1-2: Inject 0.0625mg/0.25ml subcutaneously QOD  • Weeks 3-4: Inject 0.125mg/0.50ml subcutaneously QOD  • Weeks 5-6: Inject 0.1875mg/0.75 subcutaneously QOD  • Weeks 7+: Inject 0.25mg/1ml subcutaneously QOD  Maintenance Dose: 0.25mg /1ml subcutaneously QOD  Other:		4 week supply	0	
Copaxone®	20mg Prefiled Syringe	20mg SQ QD		4 week supply		
Extavia®	40mg Prefiled Syringe  0.3mg vial	40 mg SQ 3 times a week, at least 48 hours apart on the same 3 days each week  Dose Titration:  • Weeks 1-2: Inject 0.0625mg/0.25ml subcutaneously QOD  • Weeks 3-4: Inject 0.125mg/0.50ml subcutaneously QOD  • Weeks 5-6: Inject 0.1875mg/0.75 subcutaneously QOD  • Weeks 7+: Inject 0.25mg/1ml subcutaneously QOD  Maintenance Dose: 0.25mg /1ml subcutaneously QOD  Other:		4 week supply	0	
Glatopa®	20mg Prefiled Syringe	20mg SQ QD		4 week supply		
Gilenya®	0.5mg capsule	Take 0.5mg po QD		4 week supply		
Rebif® Rebif Redidose®	Titration Pack (8.8mcg/22mcg) 22mcg Prefilled Syringe 44mcg Prefilled Syringe	Inject 8.8mcg subcutaneously three times a week weeks 1-2, 22mcg subcutaneously three times a week weeks 3-4, and 44mcg subcutaneously three times a week weeks 5+ (48 hours apart)  Maintenance: Inject 22mcg (0.5ml) SQ three times a week (48 hours apart)  Maintenance: Inject 44mcg (0.5ml) SQ three times a week (48 hours apart)		4 week supply	0	
		Other:				
Patient S	upport Programs: Please sign ar	nd date below to er	nroll in the pharmaceutical company assisted patient s	support prograr	n	
Patient Signature:			Date:			
	Prescri	<b>ber Signature:</b> Pre	scriber, please sign and date below			
Dispense as written			Substitution Permissable			
PISPERISE AS WITHER		Date	- Substitution i Cimissubic	Date		

Pursuant to VA/OH/MO/VT law, only 1 medication is permitted per order form. Please use a new form for additional items.